Survivin and molecular pathogenesis of colorectal cancer

Lancet

Volumn 362, Issue 9379, 2003, Pages 205-209

  Kim, Paul J ^a   Plescia, Janet ^a   Clevers, Hans ^b   Fearon, Eric R ^c   Altieri, Dario C ^a,d  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b Centre for Biomedical Genetics   (Netherlands)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d Department of Cancer Biology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA CATENIN; SURVIVIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; EMBRYO; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTESTINE CRYPT; KNOCKOUT MOUSE; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

EID: 0038498213     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13910-4     Document Type: Article

References (28)

1. Taipale J., Beachy P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature. 411:2001;349-354.
2. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 87:1996;159-170.
3. Bienz M., Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 103:2000;311-320.
4. Polakis P. Wnt signaling and cancer. Genes Dev. 14:2000;1837-1851.
5. Cadigan K.M., Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 11:1997;3286-3305.
6. Fodde R., Smits R., Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 1:2001;55-67.
7. Korinek V., Barker N., Morin P.J., et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science. 275:1997;1784-1787.
8. Morin P.J., Sparks A.B., Korinek V., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 275:1997;1787-1790.
9. Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 398:1999;422-426.
10. He T.C., Sparks A.B., Rago C., et al. Identification of c-MYC as a target of the APC pathway. Science. 281:1998;1509-1512.
11. Nusse R. The Wnt gene homepage. http://www.stanford.edu/~musse/wntwindow.html (accessed July 3, 2003).
12. Morin P.J., Vogelstein B., Kinzler K.W. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci USA. 93:1996;7950-7954.
13. You Z., Saims D., Chen S., et al. Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol. 157:2002;429-440.
14. Salvesen G.S., Duckett C.S. Apoptosis: IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol. 3:2002;401-410.
15. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 3:2003;46-54.
16. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58:1998;5071-5074.
17. Sarela A.I., Scott N., Ramsdale J., Markham A.F., Guillou P.J. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol. 8:2001;305-310.
18. Li F., Altieri D.C. Transcriptional analysis of human survivin gene expression. Biochem J. 344:1999;305-311.
19. Kolligs F.T., Hu G., Dang C.V., Fearon E.R. Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol. 19:1999;5696-5706.
20. Adida C., Crotty P.L., McGrath J., Berrebi D., Diebold J., Altieri D.C. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol. 152:1998;43-49.
21. Korinek V., Barker N., Moerer P., et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet. 19:1998;379-383.
22. Grossman D., McNiff J.M., Li F., Altieri D.C. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 113:1999;1076-1081.
23. Mesri M., Wall N.R., Li J., Kim R.W., Altieri D.C. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest. 108:2001;981-990.
24. van de Wetering M., Oosterwegel M., Dooijes D., Clevers H. Identification and cloning of TCF-1, a T lymphocyte-specific transcription factor containing a sequence-specific HMG box. Embo J. 10:1991;123-132.
25. Zhang T., Otevrel T., Gao Z., Ehrlich S.M., Fields J.Z., Boman B.M. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 61:2001;8664-8667.
26. Adida C., Berrebi D., Peuchmaur M., Reyes-Mugica M., Altieri D.C. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 351:1998;882-883.
27. Smith S.D., Wheeler M.A., Plescia J., Colberg J.W., Weiss R.M., Altieri D.C. Urine detection of survivin and diagnosis of bladder cancer. JAMA. 285:2001;324-328.
28. van de Wetering M., Sancho E., Vervweij C., et al. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 111:2002;241-250.